Kathryn H. Milne

TL;DR: It is demonstrated that Pf RH5-based vaccines can protect Aotus monkeys against a virulent vaccine-heterologous P. falciparum challenge and suggested that PfRH5- based vaccines have potential to achieve strain-transcending efficacy in humans.

TL;DR: A blood-stage P. falciparum CHMI model is used to assess blood- stage vaccine candidates, using their impact on the parasite multiplication rate (PMR) as the primary efficacy end point, and induced highly reproducible infection in all volunteers and will accelerate proof-of-concept testing of futureBlood-stage vaccine candidates.

TL;DR: These data provide the first in-depth assessment of the quality of adenovirus-MVA vaccine-induced antibody responses in humans, along with assessment of how these responses are modulated by subsequent low-density parasite exposure.

TL;DR: It is demonstrated for the first time to the authors' knowledge that strain-transcending antibodies can be induced against the PvDBP_RII antigen by vaccination in humans.

TL;DR: The ability to improve the potency of a relatively weak aluminium-based adjuvant in humans, by previously priming with an adenoviral vaccine vector encoding the same antigen, thus offers a novel vaccination strategy for difficult or neglected disease targets when access to more potent adjuvants is not possible.